The goal of the Moffitt Cancer Center (MCC) Cancer Epidemiology (CE) Program is to contribute to a reduction in the cancer burden through research to identify risk factors across the cancer continuum comprising etiology, progression, and outcome, and the translation of that knowledge into successful prevention and early detection interventions. Rapid increases in information enabled by advances in technology have provided the opportunity to clarify underlying causes of cancer pathogenesis. The complexity of the collection of diseases known as cancer requires a robust approach and consideration for a broad array of biomarkers. The identification of markers that alter susceptibility to cancer allows for the development and testing of clinical cancer prevention strategies. To achieve its goal, the CE Program is organized into three specific aims focused on 1) identification and testing of acquired biomarkers of cancer risk and outcome, 2) examination of inherited susceptibility markers and associations with cancer risk and outcome, and 3) discovery and testing of promising approaches for the prevention and early detection of cancer. CE members investigate how biomarkers, some of which are modifiable, impact disease onset, progression, and outcome and whether these biomarkers can be brought forward into the clinical and public health realms for translational impact. Work is conducted in close collaboration with colleagues in the Health Outcomes and Behavior (HOB) Program, who seek to better understand behaviors that affect mutable biomarkers and modify those behaviors to decrease cancer risk and promote early detection. Thus, the specific aims of CE are highly complementary to those of HOB, and there is considerable synergy between members of both programs. The program comprises 24 members from six academic departments. Peer-reviewed funding is $6.7M in annual total costs, and the portion of this funding derived from NCI is $5.8M, representing 86% of the program's peer-reviewed funding. Program members have published 635 cancer-relevant scholarly articles including 58 in high impact journals (impact factor >10). In total, 174 (27%) of all publications represent intra- programmatic collaborations, 147 (23%) represent inter-programmatic collaborations, and 292 (46%) reflect inter-institutional collaborations with other NCI-designated Cancer Centers. Indeed, CE members currently have 37 inter-institutional collaborative awards. Scientific investigations led by program members have helped advance knowledge of risk factors, including methylation markers, human papilloma and other viruses, microRNA signatures, and genetic polymorphisms, for numerous cancers that are the major contributors to mortality and morbidity in the MCC catchment area, and for other cancers. CE Program members also are active in translating their work through developing better vaccines, botanical chemopreventive agents, and automated digital imaging to impact clinical and public health practice.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA076292-19
Application #
9209828
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Project Start
Project End
Budget Start
2017-02-01
Budget End
2018-01-31
Support Year
19
Fiscal Year
2017
Total Cost
$31,375
Indirect Cost
$13,134
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
Research Institutes
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Davis, Stacy N; Christy, Shannon M; Chavarria, Enmanuel A et al. (2017) A randomized controlled trial of a multicomponent, targeted, low-literacy educational intervention compared with a nontargeted intervention to boost colorectal cancer screening with fecal immunochemical testing in community clinics. Cancer 123:1390-1400
Song, Jinming; Hussaini, Mohammad; Zhang, Hailing et al. (2017) Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis. Am J Clin Pathol 147:444-452
Tauro, Marilena; Shay, Gemma; Sansil, Samer S et al. (2017) Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth. Mol Cancer Ther 16:494-505
Heit, Claire; Marshall, Stephanie; Singh, Surrendra et al. (2017) Catalase deletion promotes prediabetic phenotype in mice. Free Radic Biol Med 103:48-56
Eksioglu, E A; Chen, X; Heider, K-H et al. (2017) Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858. Leukemia 31:2172-2180
Strom, Tobin; Harrison, Louis B; Giuliano, Anna R et al. (2017) Tumour radiosensitivity is associated with immune activation in solid tumours. Eur J Cancer 84:304-314
Liu, Ying; Balagurunathan, Yoganand; Atwater, Thomas et al. (2017) Radiological Image Traits Predictive of Cancer Status in Pulmonary Nodules. Clin Cancer Res 23:1442-1449
Chen, Yi; Fisher, Kate J; Lloyd, Mark et al. (2017) Multiplexed Liquid Chromatography-Multiple Reaction Monitoring Mass Spectrometry Quantification of Cancer Signaling Proteins. Methods Mol Biol 1647:19-45
Kamath, Vidya P; Torres-Roca, Javier F; Eschrich, Steven A (2017) Integrating Biological Covariates into Gene Expression-Based Predictors of Radiation Sensitivity. Int J Genomics 2017:6576840
Ahmed, Kamran A; Berglund, Anders E; Welsh, Eric A et al. (2017) The radiosensitivity of brain metastases based upon primary histology utilizing a multigene index of tumor radiosensitivity. Neuro Oncol 19:1145-1146

Showing the most recent 10 out of 1137 publications